Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial

Abstract The prognostic value of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at baseline or the predictive value of minimal residual disease (MRD) detection appear as potential tools to improve mantle cell lymphoma (MCL) patients’ management. The LyMa-101, a...

Full description

Bibliographic Details
Main Authors:	Caroline Bodet-Milin, Cyrille Morvant, Thomas Carlier, Gauthier Frecon, Olivier Tournilhac, Violaine Safar, Françoise Kraeber-Bodere, Steven Le Gouill, Elizabeth Macintyre, Clément Bailly
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-10-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-45215-y

Similar Items

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
by: Clément Bailly, et al.
Published: (2020-01-01)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
by: Clément Bailly, et al.
Published: (2019-04-01)

Reply to E. Laffon et al.
by: Clément Bailly, et al.
Published: (2020-01-01)

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
by: Caroline Bodet-Milin, et al.
Published: (2008-03-01)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
by: Clement Bailly, et al.
Published: (2017-01-01)

Modelling Lyman α forest cross-correlations with LyMAS
by: Lochhaas, C, et al.
Published: (2016)

Modeling Lyman-α Forest Cross-Correlations with LyMAS
by: Lochhaas, C, et al.
Published: (2016)

Interest of Pet Imaging in Multiple Myeloma
by: Bastien Jamet, et al.
Published: (2019-04-01)

Prognostic value of 18F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
by: Eric Laffon, et al.
Published: (2020-01-01)

FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma
by: Pierre-Yves Salaun, et al.
Published: (2008-08-01)

Prognostic value and clinical impact of 18FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy.
by: clement eBailly, et al.
Published: (2014-12-01)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.
by: Clément Bailly, et al.
Published: (2016-01-01)

DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach
by: Bastien Jamet, et al.
Published: (2024-07-01)

Immuno-PET: Design options and clinical proof-of-concept
by: Alexandre Lugat, et al.
Published: (2022-10-01)

Pretargeting for imaging and therapy in oncological nuclear medicine
by: Clément Bailly, et al.
Published: (2017-06-01)

QUANTITATIVE EVALUATION OF THERAPEUTIC RESPONSE BY FDG PET-CT IN METASTATIC BREAST CANCER
by: Dorothée eGOULON, et al.
Published: (2016-05-01)

[18F]-Fludarabine for Hematological Malignancies
by: Louisa Barré, et al.
Published: (2019-04-01)

LyMAS reloaded: improving the predictions of the large-scale Lyman-α forest statistics from dark matter density and velocity fields
by: Peirani, S, et al.
Published: (2022)

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
by: Thomas Carlier, et al.
Published: (2020-09-01)

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin’s disease
by: Catherine Ansquer, et al.
Published: (2008-01-01)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
by: Caroline Bodet-Milin, et al.
Published: (2019-06-01)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
by: Clément Bailly, et al.
Published: (2019-07-01)

CLINICAL AND SURVIVAL IMPACT OF FDG PET IN PATIENTS WITH SUSPICION OF RECURRENT OVARIAN CANCER: A 6-YEAR FOLLOW-UP
by: Daniela eRusu, et al.
Published: (2015-07-01)

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography
by: Caroline Bodet-Milin, et al.
Published: (2008-03-01)

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
by: Kraeber-Bodéré, F, et al.
Published: (2012)

Specific features to differentiate Giant cell arteritis aortitis from aortic atheroma using FDG-PET/CT
by: Olivier Espitia, et al.
Published: (2021-08-01)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
by: Clementine Sarkozy, et al.
Published: (2023-08-01)

Assessment of lymph nodes and prostate status using early dynamic curves with 18F-choline PET/CT in prostate cancer
by: Cédric eMathieu, et al.
Published: (2015-09-01)

Challenges in nuclear medicine: innovative theranostic tools for personalized medicine
by: Françoise eKraeber-Bodéré, et al.
Published: (2014-07-01)

The Impact of Artificial Intelligence CNN Based Denoising on FDG PET Radiomics
by: Cyril Jaudet, et al.
Published: (2021-08-01)

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases
by: Baptiste Pichon, et al.
Published: (2020-11-01)

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
by: Caroline eBodet-Milin, et al.
Published: (2015-11-01)

Role of FDG-PET Radiomics in the Diagnosis of Cardiovascular Inflammation: A Narrative Review
by: Nora Almuqbil
Published: (2024-06-01)

Assessment of the risk of contracting Lyme disease in areas with significant human presence Risco de contrair doença de Lyma em áreas com significativa presença humana
by: M. Milutinovic, et al.
Published: (2008-02-01)

Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
by: Caroline eBodet-Milin, et al.
Published: (2013-07-01)

FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
by: M. Pavic, et al.
Published: (2020-07-01)

Radiomics–clinical nomogram based on pretreatment 18F-FDG PET-CT radiomics features for individualized prediction of local failure in nasopharyngeal carcinoma
by: Jianming Ding, et al.
Published: (2023-10-01)

Cell Tracking in Cancer Immunotherapy
by: Justine Perrin, et al.
Published: (2020-02-01)

Does consensus contour improve robustness and accuracy in 18F-FDG PET radiomic features?
by: Mingzan Zhuang, et al.
Published: (2024-06-01)

The Influence of the Exclusion of Central Necrosis on [<sup>18</sup>F]FDG PET Radiomic Analysis
by: Wyanne A. Noortman, et al.
Published: (2021-07-01)